These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31399813)

  • 1. [New slow-release buprenorphine formulations for optimization of opioid substitution].
    Soyka M; Pogarell O
    Nervenarzt; 2019 Sep; 90(9):932-937. PubMed ID: 31399813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
    Soyka M
    Pharmacopsychiatry; 2021 Jan; 54(1):18-22. PubMed ID: 33212514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations.
    Soyka M; Franke AG
    World J Psychiatry; 2021 Sep; 11(9):543-552. PubMed ID: 34631459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
    Soyka M; Groß G
    Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.
    Vorspan F; Hjelmström P; Simon N; Benyamina A; Dervaux A; Brousse G; Jamain T; Kosim M; Rolland B
    Expert Opin Drug Deliv; 2019 Sep; 16(9):907-914. PubMed ID: 31364884
    [No Abstract]   [Full Text] [Related]  

  • 6. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
    Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
    Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Opioid Substitution Treatment in Prisons: Comparison of Cost of Buprenorphine Depot with other Medications - a Health-Economic Calculation].
    Stöver H; Keppler K
    Gesundheitswesen; 2023 Jun; 85(6):573-577. PubMed ID: 35921849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine implants in medical treatment of opioid addiction.
    Chavoustie S; Frost M; Snyder O; Owen J; Darwish M; Dammerman R; Sanjurjo V
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):799-807. PubMed ID: 28571505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.
    Dunlop AJ; White B; Roberts J; Cretikos M; Attalla D; Ling R; Searles A; Mackson J; Doyle MF; McEntyre E; Attia J; Oldmeadow C; Howard MV; Murrell T; Haber PS; Lintzeris N
    Addiction; 2022 Feb; 117(2):382-391. PubMed ID: 34184798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
    Tompkins CNE; Neale J; Strang J
    J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged-release buprenorphine formulations: Perspectives for clinical practice.
    Chappuy M; Trojak B; Nubukpo P; Bachellier J; Bendimerad P; Brousse G; Rolland B
    Therapie; 2020; 75(5):397-406. PubMed ID: 32499082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compared implementation of the long-acting buprenorphine treatment buvidal in four European countries.
    Rolland B; Matheson C; Kaski A; Kosim M; Roncero C; Vorspan F
    Expert Opin Drug Deliv; 2024 May; 21(5):809-815. PubMed ID: 38898689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
    Neale J; Tompkins CNE; Strang J
    Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
    Gastberger S; Baumgartner MR; Soyka M; Quednow BB; Hulka LM; Herdener M; Seifritz E; Mutschler J
    Eur Addict Res; 2019; 25(4):207-212. PubMed ID: 31067528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes.
    Hammerslag LR; Talbert J; Slavova S; Lei F; Freeman PR; Marks KR; Fanucchi LC; Walsh SL; Lofwall MR
    J Subst Use Addict Treat; 2024 Sep; 164():209391. PubMed ID: 38740189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges.
    Arunogiri S; Lintzeris N
    J Subst Abuse Treat; 2021 May; 124():108221. PubMed ID: 33303254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
    Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze P; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M
    Addiction; 2020 Jul; 115(7):1295-1305. PubMed ID: 31860767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and misuse of opioid agonists in opioid addiction.
    Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
    Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition From Methadone to Buprenorphine Using a Short-acting Agonist Bridge in the Inpatient Setting: A Case Study.
    Callan J; Pytell J; Ross J; Rastegar DA
    J Addict Med; 2020; 14(5):e274-e276. PubMed ID: 31977358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.